To print: Select File and then Print from your browser's menu --------------------------------------------------------------------------------------- Title: Zoladex May Further Reduce Breast Cancer Recurrence In Premenopausal Women URL: http://www.pslgroup.com/dg/14FB1E.htm Doctor's Guide December 10, 1999
SAN ANTONIO, TX -- December 10, 1999 -- Several presentations involving AstraZeneca's new breast cancer drugs were made at the 22nd Annual San Antonio Breast Cancer Symposium, one of the world's leading meetings devoted to new advances in breast cancer. New studies on early breast cancer in young (premenopausal) women indicate that Zoladex (goserelin acetate) treatment, in addition to other standard adjuvant treatments including Nolvadex (tamoxifen citrate), may protect against a recurrence of the disease.(1) Results from the ZIPP (Zoladex in Premenopausal Patients) study, show that the addition of Zoladex to standard therapy after surgery in young women reduced recurrences of breast cancer, irrespective of whether or not they had also received tamoxifen or chemotherapy. The analysis, conducted by researchers from Europe including the Cancer Research Campaign & UCL Cancer Trial Center in London, included 2631 premenopausal patients from four studies who were followed over 4.3 years. It was designed to measure the efficacy of Zoladex as an addition to standard treatment (surgery with or without radiotherapy or tamoxifen or chemotherapy) in young women with early-stage breast cancer. Unlike many other therapies, Zoladex induces a reversible form of ovarian suppression, thus potentially preserving reproductive capabilities for younger breast cancer patients. An estimated 176,300 new cases of breast cancer will be diagnosed in the US this year.(2) More than 50,800 of these women will be under the age of 50.(3) Zoladex is one of the few hormonal therapies currently approved for young women with advanced breast cancer. These new data indicates that young women with earlier stages of the disease may benefit from Zoladex, offering them a new hormonal therapy and increasing their treatment options. References: 1. Baum, M. et. al., "ZIPP trial," CRC & UCL Cancer Trial Center, London. Presented at the 22nd Annual San Antonio Breast Cancer Symposium, 1999. 2. CA Journal for Clinicians American Cancer Society. Cancer Statistics-1999. Jan/Feb 1999 Vol 49, No. 1. 3. Breast Cancer Facts and Figures. The American Cancer Society, 1999-2000. Related Links: Tamoxifen (tamoxifen citrate), Zoladex (goserelin acetate), Astra and Zeneca. --------------------------------------------------------------------------------------------- Copyright © 1999 P\S\L Consulting Group Inc. All rights reserved. Republication or redistribution of P\S\L content is expressly prohibited without the prior written consent of P\S\L. P\S\L shall not be liable for any errors, omissions or delays in this content or any other content on its sites, newsletters or other publications, nor for any decisions or actions taken in reliance on such content. --------------------------------------------------------------------------------------------- This news story was printed from *Doctor's Guide to the Internet* located at http://www.docguide.com --------------------------------------------------------------------------------------- Return to News Story Page This site is maintained by webmaster@pslgroup.com Please contact us with any comments, problems or bugs. All contents Copyright (c) 1998 P\S\L Consulting Group Inc. All rights reserved.